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ABSTRACT
Introduction: Pressurized metered-dose
inhalers (pMDI) such as fluticasone propionate
and salmeterol (FP/SAL) are commonly used for
the treatment of asthma in the UK. Previously, a
budget impact analysis demonstrated that use
of FP and formoterol fumarate (FP/FORM) pMDI
as an alternative to FP/SAL pMDI, would be a
cost-saving option for the UK National Health
Service (NHS). This budget impact analysis
aimed to update the existing analysis with
prescription volume data and real-world
evidence since the introduction of FP/FORM to
the UK market.
Methods: Patient Data (IMS Information
Solutions UK Ltd) moving annual total (MAT)
August 2015 were used to ascertain the number
of units of pMDI prescribed. Annual costs to the
NHS in terms of drug, administration,
monitoring and adverse event costs, were used
to estimate the potential budget impact for FP/
FORM and FP/SAL. Costs were calculated for
current prescription volumes (12% FP/FORM,
88% FP/SAL), and for different prescription
volume scenarios (FP/FORM at 0%, 25%, 50%
and 100%). Real-world evidence and budget
impact at a clinical commissioning group
(CCG) level were also considered.
Results: Total annual costs per person year
were less with FP/FORM (£625) than with FP/
SAL (£734). Annual costs to the NHS based on
the current prescription volumes and clinical
trial data were estimated at £210.0M, however,
based on real-world evidence, costs were
estimated at £179.8M. For all scenarios with
increased FP/FORM prescription volumes, the
annual total costs to the NHS decreased. This
was reflected at a CCG level.
Conclusion: The use of FP/FORM as an
alternative to FP/SAL can result in cost savings
for the NHS when assessing drug,
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administration, monitoring and adverse events
costs. The inclusion of data released since the
launch of FP/FORM within the budget impact
analysis demonstrates that the potential cost
savings to the NHS that were previously
published are being translated to clinical
practice.
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Currently, 5.4 million people in the UK are
receiving treatment for asthma [1], which is
associated with a substantial economic burden:
the annual National Health Service (NHS)
expenditure associated with treating and
caring for asthma patients, in terms of drug
costs, hospital admissions and general
practitioner (GP) visits, was estimated to be
approximately £1 billion in the UK [1].
There are a number of treatments available
for asthma patients, and combination inhaled
corticosteroid (ICS) and long-acting beta
agonists (LABA) inhalers are recommended for
the treatment of patients with asthma who are
not controlled with ICS alone [2]. These
combination inhalers are as effective at
delivering the drug as individual component
inhalers but may provide additional benefits in
terms of safety (by ensuring the LABA
component is not taken without the ICS
component) and patient adherence [3, 4].
There are two main types of combination ICS/
LABA inhaler devices: the pressurized
metered-dose inhaler (pMDI) and dry powder
inhaler (DPI). Of these two main options, there
may be benefits of using pMDIs over DPIs. For
example, a recent study demonstrated that
pMDIs, as opposed to DPIs, are associated with
increased adherence in clinical practice, fewer
exacerbations and lower health costs [5].
Within the UK, Seretide (GlaxoSmithKline,
Brentford, UK) (fluticasone propionate and
salmeterol xinafoate; [FP/SAL]) has the greatest
volume of ICS/LABA units prescribed for the
treatment of patients diagnosed with asthma,
accounting for 51.8% of the market, and is
available within Accuhaler (GlaxoSmithKline,
Brentford, UK) (DPI) and Evohaler
(GlaxoSmithKline, Brentford, UK) (pMDI)
device types [6]. flutiform (Jagotec AG,
Cambridge, UK) (FP and formoterol fumarate;
FP/FORM) pMDI entered the UK market in
2013, and currently accounts for 4.6% of
overall ICS/LABA units prescribed for patients
with an asthma diagnosis [6].
Prior to the introduction of FP/FORM, a
budget impact model was developed to
evaluate the impact for the NHS of using FP/
FORM as an alternative treatment to FP/SAL [7].
The comparable efficacy of FP/FORM to FP/SAL
had been previously demonstrated in patients
aged C18 years with persistent asthma for
C6 months in an open-label, randomized,
active-controlled, parallel-group, multicenter,
Phase III non-inferiority study [8, 9]. Based on
projected FP/FORM uptake scenarios, the
previous model demonstrated that switching
from FP/SAL to FP/FORM could result in savings
to the NHS [7]. Since the introduction of FP/
FORM to the UK market, data demonstrating
the effectiveness and resource use impact of FP/
FORM in real-world settings have become
available, which may impact upon the
previously modeled outputs [10]. The
real-world data showed that patients who
switched from FP/SAL to FP/FORM had fewer
asthma consultations (with or without
prescription of oral steroids) (1.4 for FP/FORM
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versus 1.8 for FP/SAL; p = 0.001) and also
confirmed that FP/FORM is non-inferior to FP/
SAL in terms of preventing severe exacerbations
[10].
Aims
The aims of this update to the budget impact
analysis were twofold: to update the existing
budget impact model with prescription volume
data since the introduction of FP/FORM to the
UK market, and to compare the results of the
budget impact model base-case with newly
available real-world evidence to evaluate the
use of FP/FORM in clinical practice, as
compared to FP/SAL.
METHODS
Update of Budget Impact Model
The full methodology of the existing budget
impact model has been published previously
[7]. In addition to the previous analyses, the
updated model also considers the inputs of
adverse events (AEs) within the base-case
scenario, instead of inclusion in a scenario
analysis. Furthermore, the update considers
real-world evidence, which has become
available since FP/FORM entered the market.
Comparators
As with the previous model, Seretide Evohaler
(FP/SAL) was considered to be the most
appropriate comparator to FP/FORM for
analysis of the budget impact to the NHS as it
is in the same pMDI device type [7]. Due to
differences in device handling, it was assumed
patients were less likely to switch between DPIs
and pMDIs, thus DPIs were excluded from the
analysis. As discussed in the previous
publication [7], in the UK it is unlikely that
patients would be switched from BDP/FORM to
FP/FORM, thus BDP/FORM was excluded from
the analysis.
SirduplaTM (Mylan, Hatfield, UK), a generic
FP/SAL launched in June 2015 in the UK, was
not considered within the model. This is
because FP/SAL is listed as Category C within
the drugs tariff in the UK [11], meaning that
generic prescription prices are linked to the
originator brand list price [12]. Moreover,
Sirdupla is only available in two doses (125
and 250 lg), and due to the recent launch,
uptake of Sirdupla was unknown.
Analysis Approach
A budget impact calculation based on
drug-related and monitoring costs was
performed to estimate the impact of using
either FP/FORM or FP/SAL in terms of cost to
the NHS, in patients with asthma (Table 1). The
impact was assessed over a 1 year time horizon,
in line with the standard timeframe for NHS
budgeting in the UK. The budget impact was
estimated assuming that the total number of
units of pMDIs prescribed each year will remain
constant but that FP/FORM may be used as an
alternative to FP/SAL in a certain proportion of
patients.
Drug-related costs included drug acquisition
costs, monitoring costs, and administration
costs; these were based on product labels, UK
reference costs and global initiative for asthma
(GINA) guidelines. AE-associated costs were
based on rates from the head-to-head
non-inferiority study of FP/FORM versus FP/
SAL [8], a GP visit and a 1 week course of
antibiotics (Augmentin) for infections and
infestations.
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As per the previous model, secondary
endpoints such as disease-related outcomes
and associated costs were not included, as the
head-to-head non-inferiority trial for FP/FORM
versus FP/SAL demonstrated no significant




Annual Units Prescribed Patient Data were
used to ascertain the number of units prescribed
of FP/FORM and FP/SAL for patients with an
asthma diagnosis within the UK [6]. Data were
obtained from MAT August 2015 data, covering
units prescribed from 1 September 2014 to 31
August 2015 [6]. The Patient Data contain
details of a patient’s age and their diagnosis
(asthma or chronic obstructive pulmonary
disease [COPD]) at any point in the patients’
primary care medical record (in this case, a
patient would be classified as an asthma patient
if they have ever had a diagnosis of asthma
recorded (and no diagnosis of COPD) or had a
spirometry test which confirms reversibility) [6].
Therefore, specific details on different age
groups of patients were available for use in
this analysis.
The number of FP/FORM pMDI units
prescribed for patients with an asthma
diagnosis was obtained from the Patient Data
[6]. In accordance with the label, data for the 50
and 125 lg doses were taken from patients aged
12 and over, whereas units prescribed for 250 lg
were taken from those aged 18 and over. The
number of FP/SAL pMDI units prescribed was
taken from the corresponding age groups for
the Evohaler device (Table 1).
Drug-Related Costs Drug acquisition costs
were calculated using unit costs from the
British National Formulary (BNF), October
2015 for the following doses: 50, 125, and
250 lg [13]. The average prescription volume
of each dose (50, 125, and 250 lg) across both
therapies (FP/FORM and FP/SAL) was calculated
to provide weighted costs for each dose of the
two therapies [Table 1, (referred to as ‘‘D’’ in the
calculation)]. The number of units prescribed
per patient per year was calculated as number of
days per year divided by the days supplied per
unit (365.25/30 = 12.175 units) (Table 1). Total
relative costs for each pMDI were multiplied by
the number of units prescribed per patient per
year to provide total drug acquisition costs per
pMDI.
It was assumed that administration costs
would not differ between FP/FORM and FP/SAL
as the device type (pMDI) is the same for both.
Administration costs were assumed to require
0.25 h of GP nurse time for training across both
device types (Table 1).
It was assumed that monitoring costs would
not differ between pMDIs as GINA guidelines
(2015) state that patients should be seen
1–3 months after initiation of any treatment
and every 3–12 months after that [2]. To be
consistent with the previous budget impact
analysis [7] and to be in line with the new
GINA guidelines, it was assumed that patients
were seen four times per year and costed
according to the Personal Social Services
Research Unit (PSSRU) for GP visits (Table 1)
[14]. However, as there is uncertainty over the
level of consultations due to the broad range
given in the GINA guidelines, this assumption
was tested using the real-world data, which
reported the average number of asthma
consultations, in a scenario analysis.
AE rates were based on infestations and
infections data from a 12-week head-to-head
non-inferiority trial FP/FORM (13.9%) versus
FP/SAL (12.9%) (the two treatment groups
Adv Ther (2016) 33:794–806 799
overall had similar safety and tolerability
profiles, and infections and infestations were
the most commonly reported AE) [8]. The cost
per AE was assumed to be equivalent between
treatments and based on one GP visit (costed
according to PSSRU) and one course of
Augmentin (costed according to BNF, October
2015) [13, 14]. Costs were estimated according
for 12 weeks and extrapolated to 1 year based
on the assumption that AEs would continue at
the same rate throughout the year (Table 1).
Budget Impact Analysis
Cost Per Person Year
Costs per person year were calculated based on
the sum of the total drug-related and
monitoring costs (Table 1).
Annual Costs for the NHS
Annual costs for the NHS were calculated based
on the multiplication of drug acquisition,
training, AE and monitoring cost estimates per
person year with the person-years on each
treatment. The base-case considered the
current scenario: FP/FORM at a prescription
volume of 12% and FP/SAL prescription volume
of 88% [of the total patients being prescribed
either FP/FORM or FP/SAL in the appropriate
age groups (Table 1)]. Further prescription
volume scenarios were considered, with
prescription volumes of FP/FORM at 0%, 25%,
50% and 100%.
Calculation
The total annual costs for treatment per person
per year (Ci, [i = treatment, where i = 1 refers to
FP/SAL, i = 2 refers to FP/FORM]) were
calculated by summing the weighted drug
acquisition costs (D), GP visits for monitoring
(M), nurse time for administration training (T),




To assess budget impact to the NHS, the total
budget impact (TBI) associated with FP/FORM
and FP/SAL was calculated as follows (where Pi is
the annual number of person-years on
treatment and Ui is the percentage prescription
volume; [i = 1 refers to FP/SAL, i = 2 refers to FP/
FORM]):
TBI ¼ ððP1 þ P2ÞU1C1Þ þ ððP1 þ P2ÞU2C2Þ
CCG Level Data
The average cost for a typical clinical
commissioning group (CCG) in the UK was also
considered for the current prescription volume
and all other scenarios in which FP/FORM
prescription volume is 0%, 25%, 50% and 100%.
There are 209 CCGs in England, each
commissioning care for an average of 250,000
people, which is approximately 0.39%of the total
UKpopulation of 64.6million [15, 16]. Therefore,
the total annual NHS-level budget impact for FP/
FORM and FP/SAL was multiplied by 0.39% to
provide the estimated CCG level budget impact.
Scenario 1: Real-World Data
Scenario 1 utilized monitoring costs from a UK
retrospective observational real-world study
which included FP/FORM and FP/SAL,
replacing the estimated number of
consultations based on the GINA guidelines
used for the base-case with the actual average
number of consultations that occurred over
1 year in the real-world study) (Table 2) [10].
This scenario analysis was applied to each of the
prescription volume analyses described above.
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Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Base-Case Analysis
Cost Per Person Year
Annual drug acquisition costs were lower with
FP/FORM (£397) than with FP/SAL (£508), while
annual administration training (£13) and
monitoring costs (£184) were the same for
both combination therapies. AE costs were
very slightly higher with FP/FORM (£31) than
FP/SAL (£29). The cost per person year based on
the current prescription volume data was £109
less with FP/FORM (£625) than with FP/SAL
(£734) (Fig. 1).
Cost to NHS
Annual costs to NHS are presented in Fig. 2.
The costs to the NHS based on the current
prescription volume (FP/FORM 12%, FP/SAL
88%) were estimated at £210.0M. With
increased FP/FORM prescription volume, the
total costs of the FP/FORM and FP/SAL market
to the NHS decreased to £206.0M, £198.1M
and £182.2M, for FP/FORM volume of 25%,
50% and 100%, respectively. However, with
0% prescription of FP/FORM, the budget
impact to the NHS was calculated at
£213.9M. The savings compared to no use of
FP/FORM were £3.9M, £7.9M, £15.8M, £31.7M
at 12%, 25%, 50%, 100% prescription volume
shares, respectively.
Upon scaling the national-level data to the
average size of a CCG within the UK (250,000
people, or 0.39% of the total UK population of
64.6 million) the budget impact was estimated
at approximately £812.7K for the base-case
scenario. With increased FP/FORM prescription
volumes of 25%, 50% and 100%, the budget
impact at a CCG level was calculated at
£797.2K, £766.5K and £705.0K, respectively.
However, with 0% prescription of FP/FORM,
the budget impact at CCG level was calculated
Fig. 1 Annual savings per person year associated with
using FP/FORM as an alternative to FP/SAL. FP
ﬂuticasone propionate, FORM formoterol fumarate, SAL
salmeterol
Table 2 Input parameter values for real-world evidence scenario analysis
Input parameter FP/SAL (Evohaler) FP/FORM Data source
Scenario 1: real-world evidence
Monitoring (M)a 1.8 GP visits per year
@ £46/visit
1.4 GP visits per year
@ £46/visit
Lim et al. [10] and PSSRU
2014
FP ﬂuticasone propionate, SAL Salmeterol, FORM formoterol fumarate, GP general practitioner, PSSRU Personal Social
Services Research Unit
a Letters in brackets refer to notation used in equation
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at £827.9K. The savings compared to no use of
FP/FORM were 15.2K, 30.7K, 61.4K and 122.9K
at 12%, 25%, 50%, 100% prescription volume
shares, respectively.
Scenario Analyses
Scenario 1: Real-World Data
This scenario considered monitoring cost data
from a UK real-world study [10]. In comparison
to the base-case, inclusion of real-world data
resulted in decreased costs to the NHS in all
prescription volume scenarios considered
(Fig. 2). This was driven by the differences in
the monitoring costs.
TBI to the NHS decreased from £179.8M at a
12% FP/FORM prescription volume to £175.1M,
£165.9M and £147.3M at 25%, 50% and 100%
FP/FORM prescription volume, respectively.
When FP/FORM prescription volume was
decreased to 0%, the total cost to the NHS
increased to £184.4M. The savings compared to
no use of FP/FORM were £4.6M, £9.3M, £18.5M,
£37.1M at 12%, 25%, 50%, 100% prescription
volume shares, respectively.
Using the current prescription volumes, cost
per person year was calculated at £505 for FP/
FORM and £632 for FP/SAL, saving £127 with
FP/FORM (Fig. 1).
When considering data at CCG level at the
current prescription volumes, the budget
impact was calculated as £696.0K. The budget
impact decreased with increasing FP/FORM
prescription volumes to: £677.8K, £641.9K and
£570.0 K at 25%, 50%, and 100% FP/FORM
prescription. However, with 0% prescription of
FP/FORM, the budget impact at CCG level is
estimated at £713.7K. The savings compared to
no use of FP/FORM were 17.7K, 35.9K, 71.8K,
143.7K at 12%, 25%, 50%, 100% prescription
volume shares, respectively.
DISCUSSION
This study demonstrates that the use of FP/
FORM as an alternative to FP/SAL can result in
Fig. 2 Annual costs to the NHS at current prescription volume scenario and alternative scenarios. NHS National Health
Service, FP ﬂuticasone propionate, FORM formoterol fumarate, SAL salmeterol
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cost savings compared to FP/FORM not being
available (based on 12–100% prescription
volumes of FP/FORM) for the NHS when
assessing drug, administration, monitoring
and AE costs.
The results from this analysis are consistent
with those of the previous analysis [7]. In
addition, the specific description of the Patient
Data used to ascertain prescription volume has
been improved as compared to that used in the
previous publication. A recent case study
demonstrated that in one Northern Ireland
community, 88.3% (n = 53) of patients were
successfully switched from the FP/SAL Evohaler
to FP/FORM, which resulted in savings of
£111.89 per patient over an 18-month period
[17]. Furthermore, in August 2015, FP/FORM
prices decreased (after the publication of the
case study). This is likely to further increase
savings associated with a successful switch to
FP/FORM. Given that the proportion of patients
within the community who underwent a
successful switch reached 88.3% of patients in
the case study from Northern Ireland [17], the
scenario presented in this paper with an FP/
FORM share of 50% is a realistic scenario for
clinical practice.
Consideration of data from Lim et al.
included within the real-world evidence
scenario (scenario 1) resulted in a saving to
the NHS, indicating that the use of FP/FORM as
an alternative to FP/SAL is associated with
greater savings in clinical practice, than the
costs predicted by the RCT data, subject to a
successful switch [10]. The difference in costs
between the base-case and the real-world
scenario was driven by monitoring costs.
Patients in the Lim et al. study had fewer GP
visits than recommended by the GINA
guidelines at the time of the study [10].
However, there were still fewer GP
consultations associated with FP/FORM than
FP/SAL and, therefore, less resource
consumption. As the patient population on
FP/FORM was the same as that on FP/SAL it is
likely that this difference is therapy related,
rather than driven by behavior.
Further to this, data from Lim et al.
demonstrated that FP/FORM is associated with
a lower percentage of severe exacerbations than
FP/SAL [10, 18]. This suggests that FP/FORM
may be associated with fewer hospitalizations
and requirements of rescue therapy than FP/SAL
[10]. However, due to the limited detail within
the published Lim et al. data, direct
comparisons to the RCT data for the base-case
scenario could not be made and as such,
exacerbation data from Lim et al. were not
considered within the model. Furthermore,
separate analyses based on this dataset which
have been presented at a conference
demonstrated that switching patients from FP/
SAL to FP/FORM results in non-inferior
prevention of severe asthma exacerbations but
at a statistically significant lower cost (total
respiratory-related healthcare cost per patient
was £64 lower for FP/FORM), which is in line
with the findings of our analysis [18].
Another recent study in Spain noted that
when comparing the price of FP/FORM with
other combinations of ICS/LABA, the price of
FP/FORM was significantly lower [19].
Furthermore, over the first 3 years, the Spanish
National Health Service is expected to save
nearly €4.4 million from its pharmacy budget
with the introduction of FP/FORM for the
treatment of moderate to severe asthma [19].
Furthermore, a non-interventional study on
safety and effectiveness in Germany reinforced
the findings from the clinical trials by
demonstrating that FP/FORM improves lung
function, asthma control, and asthma related
quality of life in a real-world setting: there was a
statistically significant improvement compared
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with baseline in asthma control (as measured by
the Asthma Control Test) of patients being
treated with FP/FORM over a 3-month period,
and there were also improvements seen in terms
of quality of life and other secondary efficacy
measures [20].
As noted, our analysis demonstrates that an
increased uptake of FP/FORM can result in
overall cost savings to the NHS without
adversely affecting clinical outcomes; there
have been several studies comparing FP/FORM
with FP/SAL [8, 9] and Phase III clinical trials
have demonstrated that FP/FORM is at least as
effective as, and has a faster onset of action,
than FP/SAL [8, 9]. In addition, FP/FORM has
been recommended as a suitable alternative to
other first-line ICS/LABA treatments, including
FP/SAL and BUD/FORM, by the Midlands
Therapeutics Review and Advisory Committee
[21]. The Scottish Medicines Consortium has
also recommended treatment with FP/FORM in
patients for which FP and FORM are appropriate
choices of ICS and LABA [22]. The National
Institute for Healthcare and Clinical Excellence
recommend that for patients in whom
treatment with an ICS is considered
appropriate, the least costly product should be
chosen (within its marketing authorization)
[23]. In comparison to FP/SAL, FP/FORM is
likely to be the least costly option in terms of
list price, and overall budget impact to the NHS.
CONCLUSIONS
This updated budget impact analysis
demonstrates that the use of FP/FORM within
the UK market results in potential cost savings
to the NHS. Since the launch of FP/FORM,
real-world evidence has been generated which
corroborates the results of clinical trials and
when these data are included within the budget
impact analysis, it demonstrates that the
potential cost savings to the NHS that were
previously published are likely to translate into
meaningful changes in clinical practice.
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